Want to see VOR full AI Analyst Report?

Vor Biopharma (VOR) Price & Analysis

Q: What was Vor Biopharma, Inc.’s price range in the past 12 months?

Vor Biopharma, Inc. lowest stock price was $6.50 and its highest was $53.00 in the past 12 months.

Q: What is Vor Biopharma, Inc.’s market cap?

Vor Biopharma, Inc.’s market cap is $980.22M.

Q: When is Vor Biopharma, Inc.’s upcoming earnings report date?

Vor Biopharma, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.

Q: How were Vor Biopharma, Inc.’s earnings last quarter?

Vor Biopharma, Inc. released its earnings results on May 07, 2026. The company reported -$5.11 earnings per share for the quarter, missing the consensus estimate of -$0.781 by -$4.329.

Q: Is Vor Biopharma, Inc. overvalued?

According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Vor Biopharma, Inc. pay dividends?

Vor Biopharma, Inc. does not currently pay dividends.

Q: What is Vor Biopharma, Inc.’s EPS estimate?

Vor Biopharma, Inc.’s EPS estimate is -0.7.

Q: How many shares outstanding does Vor Biopharma, Inc. have?

Vor Biopharma, Inc. has 54,185,880 shares outstanding.

Q: What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?

Vor Biopharma, Inc. reported an EPS of -$5.11 in its last earnings report, missing expectations of -$0.781. Following the earnings report the stock price went up 1.132%.

Q: Which hedge fund is a major shareholder of Vor Biopharma, Inc.?

Currently, no hedge funds are holding shares in VOR

958 Followers

VOR Stock Chart & Stats

$16.59

<$0.01(<0.01%)

At close: Jan 08 4:00 PM EST

$16.59

<$0.01(<0.01%)

Day’s Range― - ―

52-Week Range$6.50 - $53.00

Previous CloseN/A

Volume424.02K

Average Volume (3M)1.54M

Market Cap

$980.22M

Enterprise Value$278.74

Total Cash (Recent Filing)$491.52M

Total Debt (Recent Filing)$2.94M

Price to Earnings (P/E)―

Beta4.71

Next Earnings

Aug 06, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-575.83

Shares Outstanding54,185,880

10 Day Avg. Volume1,351,846

30 Day Avg. Volume1,539,713

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.79

Price to Sales (P/S)0.00

P/FCF Ratio-0.90

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$26.33

Price Target Upside58.73% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-5.71

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Absolute LeverageVery low reported debt in absolute terms reduces near-term solvency and interest burden risk, giving management flexibility to fund R&D or restructure capital. Over 2–6 months this durable low-leverage profile lowers refinancing pressure versus highly leveraged peers.

Board & Governance StrengtheningAdding a seasoned pharmaceutical executive to the board strengthens strategic oversight, commercialization and partnering experience. Durable governance improvements can aid clinical program prioritization, business development and capital access over the medium term.

External Clinical/Mechanism ValidationRegulatory approval of a BAFF/APRIL-targeting therapy in China validates the modality and reduces scientific risk for related approaches. This structural validation can improve partner interest and de-risk Vor’s platform advancement in autoimmune/hematology programs over coming months.

Bears Say

Pre-revenue ProfileNo product revenue means the firm cannot self-fund operations from sales and remains dependent on capital markets and partners. Over 2–6 months this limits operational resilience and forces trade-offs between R&D pace and cash preservation.

Persistent Heavy Cash BurnSustained negative operating and free cash flow rapidly consumes liquidity and shortens runway absent financing. This structural cash-burn profile increases the probability of dilutive financings or strategic concessions within the medium term, constraining long-term optionality.

Negative Equity & Reduced FlexibilityNegative shareholders' equity reflects accumulated losses and weakens balance-sheet credibility with lenders and partners. This durable capital-structure pressure can raise cost of capital, limit borrowing capacity, and hamper strategic transactions over coming months.

Vor Biopharma News

Vor Biopharma Adds Industry Veteran David Zaccardelli to Board

Vor Biopharma ( ($VOR) ) has issued an update. On July 6, 2026, Vor Biopharma announced that Board...

13d ago

VOR

Vor Biopharma shareholders back directors and governance measures

The latest update is out from Vor Biopharma ( ($VOR) ). At its 2026 Annual Meeting, Vor Biopharma...

1M ago

VOR

Vor Bio gains boost from telitacicept IgA nephropathy approval

The latest announcement is out from Vor Biopharma ( ($VOR) ). Vor Bio and its collaborator RemeGen Co.,...

1M ago

VOR

Vor Bio announces China NMPA approval for telitacicept

Vor Bio (VOR) and RemeGen announced that China’s National Medicinal Products Administration, or NMPA, has conditionally approved telitacicept...

1M ago

VOR

Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar

Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. The phase 3 study called “A...

2M ago

VOR

Vor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Vor Biopharma, retaining the price target of...

2M ago

VOR

Vor Bio price target raised to $18 from $15 at Wedbush

Wedbush analyst Martin Fan raised the firm’s price target on Vor Bio (VOR) to $18 from $15 and...

2M ago

VOR

Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High

Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. Vor Biopharma, Inc. is running a...

2M ago

VOR

Vor Bio files to sell 5.34M shares of common stock for holders

16:13 EDT Vor Bio (VOR) files to sell 5.34M shares of common stock for holders Published first on...

3M ago

VOR

Clene, Lovesac, HDFC Bank, State Street, Vor Shock

Insiders have been trading these 5 stocks: (($CLNN)), (($LOVE)), (($HDB)), (($STT)) and (($VOR)). Here is a breakdown of...

3M ago

HDB

STT

Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup

Insiders have been trading these 5 stocks: (($BJ)), (($ATLX)), (($ASO)), (($VOR)) and (($GLBE)). Here is a breakdown of...

3M ago

ASO

Vor Bio price target lowered to $31 from $32 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $31 from $32 and keeps a...

3M ago

VOR

Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up

Insiders have been trading these 5 stocks: (($IL:ESLT)), (($VOR)), (($GLBE)), (($SG)) and (($IMVT)). Here is a breakdown of...

3M ago

VOR

Vor Bio price target raised to $15 from $9 at Wedbush

Wedbush raised the firm’s price target on Vor Bio (VOR) to $15 from $9 and keeps a Neutral...

4M ago

VOR

VOR FAQ

What was Vor Biopharma, Inc.’s price range in the past 12 months?

Vor Biopharma, Inc. lowest stock price was $6.50 and its highest was $53.00 in the past 12 months.

What is Vor Biopharma, Inc.’s market cap?

Vor Biopharma, Inc.’s market cap is $980.22M.

When is Vor Biopharma, Inc.’s upcoming earnings report date?

Vor Biopharma, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.

How were Vor Biopharma, Inc.’s earnings last quarter?

Vor Biopharma, Inc. released its earnings results on May 07, 2026. The company reported -$5.11 earnings per share for the quarter, missing the consensus estimate of -$0.781 by -$4.329.

Is Vor Biopharma, Inc. overvalued?

According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vor Biopharma, Inc. pay dividends?

Vor Biopharma, Inc. does not currently pay dividends.

What is Vor Biopharma, Inc.’s EPS estimate?

Vor Biopharma, Inc.’s EPS estimate is -0.7.

How many shares outstanding does Vor Biopharma, Inc. have?

Vor Biopharma, Inc. has 54,185,880 shares outstanding.

What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?

Vor Biopharma, Inc. reported an EPS of -$5.11 in its last earnings report, missing expectations of -$0.781. Following the earnings report the stock price went up 1.132%.

Which hedge fund is a major shareholder of Vor Biopharma, Inc.?

Currently, no hedge funds are holding shares in VOR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vor Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

363.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vor Biopharma, Inc.

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Vor Biopharma (VOR) Earnings & Revenues

Historic Earnings Reports

VOR Stock 12 Month Forecast

Average Price Target

$26.33

▲(58.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","43":"$43","15.25":"$15.25","24.5":"$24.5","33.75":"$33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.333333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.25,24.5,33.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.39,19.36,20.330000000000002,21.3,22.27,23.240000000000002,24.21,25.18,26.15,27.12,28.09,29.060000000000002,30.03,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.39,19.00102564102564,19.612051282051283,20.223076923076924,20.834102564102565,21.445128205128206,22.056153846153848,22.66717948717949,23.27820512820513,23.88923076923077,24.500256410256412,25.111282051282053,25.722307692307695,{"y":26.333333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.39,18.36,18.330000000000002,18.3,18.27,18.240000000000002,18.21,18.18,18.15,18.12,18.09,18.06,18.03,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.39,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >